Novo Nordisk and Valo Health have collaborated on the development of cardiovascular disease drugs since 2023. Expanding the alliance to cardiometabolic diseases nearly doubles the number of programs covered under the agreement.
Novo Nordisk is paying Valo Health $60 million up front to gain three preclinical cardiovascular disease programs. Milestone payments for those programs and others covered under the artificial intelligence drug discovery pact could reach up to $2.7 billion.
Who accredits health plans for mental health parity compliance? Learn about the only organization that offers this program to ensure your members get equitable care.
Flagship Pioneering’s Valo Health and Khosla Ventures Acquisition Co. abandoned their SPAC merger on the eve of a scheduled shareholder vote on whether to approve the deal. The parties described the decision as mutual, and they cited “market conditions.”
Check out news from Vivalink, HealthMine, Vitable Health and more.
Valo Health is going public in a SPAC merger. Less than nine months removed from its formal launch, Valo is now revealing more about its artificial intelligence platform technology, which it plans to use to make the firm the first “digitally native” pharmaceutical company.